Editing cells has the potential to create safety risks to patients due to unintended genomic changes or simply not enough understanding of the impact of edits on the biology of the cells (e.g. potency, persistence, off-target/unintended signals). A-DOC has expertise in non-viral cell editing methods that are more specific and safer than viral editing approaches. We can help clients assess genomic stability and off-target editing using industry standard technologies. Working together with A-SET, we can generate actionable biological safety data both in vitro and in vivo to identify and mitigate safety concerns early in development to help clients create the safest therapy possible.